- Date2024-09-06
Publication of Review Result of the Second Pharmaceutical Reimbursement Evaluation Committee of 2023
□ The Health Insurance Review and Assessment Service (President Kim Sun-min) releases the results of the deliberations of the 2nd Pharmaceutical Reimbursement Evaluation Committee in 2023 as follows.
○ Result of the review of the adequacy of the healthcare benefit for the pharmaceutical applied for assessment
|
Product |
Pharmaceutical company |
Efficacy and effectiveness |
Deliberation results |
|
Zaledeep Cap. 5mg, 10mg(Zaleplon) |
Bukwang Co., Ltd |
Short-term treatment of insomnia in adults |
Reimbursement is adequate when accepted at or below assessed value. |
|
Ozempic Prefilled Pen (Semaglutide) |
Novo Nordisk Ltd. |
Adjuvant to diet and exercise in adults with inadequate control of type 2 diabetes |
Reimbursement is adequate when accepted at or below assessed value. |
|
Brukinsa Cap. 80mg (Janus kinase inhibito) |
Beigene Korea, Inc. |
1. Waldenstrom macroglobulinemia (WM) 2. Mantle cell lymphoma (MCL) 3. Marginal zone lymphoma (MZL) |
[1. Waldenstrom macroglobulinemia (WM)] Reimbursement is adequate. |
|
Inrebic Cap. (Fedratinib Hydrochloride Hydrate) |
BMS Korea, Inc. |
Treatment of splenomegaly or symptoms associated with the following diseases in adult patients previously treated with ruxolitinib - Primary myelofibrosis - Myelofibrosis after polycythemia vera - Myelofibrosis after essential thrombocythemia |
Reimbursement is adequate. |
|
Crysvita Inj. 10mg, 20mg, 30mg (Burosumab) |
Kyowa Kirin Korea Co., Ltd. |
FGF23-associated hypophosphatemic rickets and osteomalacia |
Reimbursement is adequate. |
※ Pursuant to Article 11(2) of the Rules on the Criteria for National Health Insurance Reimbursement, the President of the Health Insurance Review and Assessment Service evaluates the adequacy of reimbursement for drugs after deliberation by the Pharmaceutical Reimbursement Evaluation Committee. The final evaluation results may be subject to change if there are changes in the detailed reimbursement scope and items of the drug, changes in the approval of the item applied for decision, or revocation (cancellation) of the approval.
